Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2026 > Vol 7, №6 (2026) > The effect of the single nucleotide polymorphism Arg25Pro of TGFB1 gene on clinical and laboratory features and the formation of comorbid pathology associated with cardiovascular risk

The effect of the single nucleotide polymorphism Arg25Pro of TGFB1 gene on clinical and laboratory features and the formation of comorbid pathology associated with cardiovascular risk

Anife S. Gaffarova , Vladimir A. Beloglazov , Igor A. Yatskov , Elizaveta S. Ageyeva , Andrey V. Petrov

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Aim. To evaluate the influence of the Arg25Pro polymorphism of the TGFB1 gene on the clinical and laboratory parameters of ankylosing spondylitis (AS) and the formation of CVR in patients with AS.
Materials and methods. 176 patients with AS underwent genotyping for the Arg25Pro polymorphism of the SELE gene using allele-specific PCR; statistical analysis was performed using the Kruskal–Wallis test.
Results. Genotyping for the Arg25Pro polymorphism of the SELE gene was performed in 176 patients with AS using allele-specific PCR. Statistical analysis was performed using the Kruskal–Wallis test. The Arg/Pro phenotype was associated with higher values of BMI (p=0.012), creatinine (p=0.02), urea (p=0.031), uric acid (p<0.05), and the Arg-glucose variant (p=0.027). Arg/Arg homozygotes had a higher incidence of enthesitis (p=0.043) and eye lesions (p=0.024). Identification of the Arg/Pro genotype was associated with a higher incidence of stage 2 (p=0.05) and stage 2 (p=0.02) arterial hypertension (AH). Pyelonephritis was more often recorded with the Pro/Pro phenotype (p=0.05), gastrointestinal diseases – Arg/Arg (p=0.001).
Conclusion. The role of the Arg25Pro SNP of the TGFB1 gene in the development of extra-axial and extra-skeletal manifestations of AS, metabolic effects, and pathology of the kidneys and gastrointestinal tract has been demonstrated.
Keywords: ankylosing spondylitis, cardiovascular risk, comorbidity, TGFB1 gene, SNP Arg25Pro.

About the Author

Anife S. Gaffarova , Vladimir A. Beloglazov , Igor A. Yatskov , Elizaveta S. Ageyeva , Andrey V. Petrov
Anife S. Gaffarova, Vladimir A. Beloglazov, Igor A. Yatskov, Elizaveta S. Ageyeva, Andrey V. Petrov

Georgievsky Order of the Red Banner of Labor Medical Institute (structural division), Vernadsky Crimean Federal University, Simferopol, Russia

anife.gaffarova96@yandex.ru

References

1. Ramiro S, Nikiphorou E, Sepriano A et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023;82(1):19-34. DOI: 10.1136/ard-2022-223296
2. Ward MM, Deodhar A, Gensler LS et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 2019;71(10):1285-99. DOI: 10.1002/acr.24025
3. Moltó A, Etcheto A, van der Heijde D et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 2016;75(6):1016-23. DOI: 10.1136/annrheumdis-2015-208174
4. Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology (Oxford). 2020;59(Suppl.4):iv79-iv89. DOI: 10.1093/rheumatology/keaa435
5. Linde L, Ørnbjerg LM, Heegaard Brahe C et al. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching. Rheumatology (Oxford) 2024;63(7):1882-92. DOI: 10.1093/rheumatology/kead494
6. Shi LH, So H, Lam SHM et al. Early-stage hypertension defined by the 2017 ACC/AHA blood pressure guideline carries excessive cardiovascular risk in axial spondyloarthritis patients. Ther Adv Musculoskelet Dis 2024;16:1759720X241303314. DOI: 10.1177/1759720X241303314
7. Karmacharya P, Shahukhal R, Crowson CS et al. Effects of Therapies on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. Rheumatol Ther 2020;7(4):993-1009. DOI: 10.1007/s40744-020-00248-x
8. Dunning AM, Ellis PD, McBride S et al. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63(10):2610-15. 
9. Koch W, Hoppmann P, Mueller JC et al. Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler Thromb Vasc Biol 2006;26(5):1114-9. DOI: 10.1161/01.ATV.0000217747.66517.11
10. Robertson IB, Rifkin DB. Regulation of the bioavailability of TGF-β and TGF-β-related proteins. Cold Spring Harb Perspect Biol 2016;8:a021907. DOI: 10.1101/cshperspect.a021907
11. van der Paardt M, Crusius JB, García-González MA et al. Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor beta 1 (TGFB1) gene polymorphisms. Ann Rheum Dis 2005;64(4):616-9. DOI: 10.1136/ard.2004.027698
12. Liu S, Li J, Cui Y. The association of transforming growth factor beta 1 gene polymorphisms with arthritis: a systematic review and meta-analysis. Clin Exp Med 2021;21(2):331-40. DOI: 10.1007/s10238-020-00678-5
13. Jaakkola E, Crane AM, Laiho K et al. The effect of transforming growth factor beta1 gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford) 2004;43(1):32-38. DOI: 10.1093/rheumatology/keg457
14. Du L, Gong T, Yao M et al. Contribution of the polymorphism rs1800469 of transforming growth factor β in the development of myocardial infarction: meta-analysis of 5460 cases and 8413 controls (MOOSE-compliant article). Medicine (Baltimore) 2019;98(26):e15946. DOI: 10.1097/MD.0000000000015946
15. Mooney RE, Linden GJ, Winning L et al. Association of TGFB1 rs1800469 and BCMO1 rs6564851 with coronary heart disease and IL1B rs16944 with all-cause mortality in men from the Northern Ireland PRIME study. PLoS One 2022;17(8):e0273333. DOI: 10.1371/journal.pone.0273333
16. Lu Y, Boer JM, Barsova RM et al. TGFB1 genetic polymorphisms and coronary heart disease risk: a meta-analysis. BMC Med Genet 2012;13:39. DOI: 10.1186/1471-2350-13-39
17. Nakaoka H, Takahashi T, Akiyama K et al. Differential effects of chromosome 9p21 variation on subphenotypes of intracranial aneurysm: site distribution. Stroke 2010;41(8):1593-98. DOI: 10.1161/STROKEAHA.110.586529
18. Hong Q, Kim H, Cai GY et al. Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy. Int J Biol Sci 2025;21(4):1649-65. DOI: 10.7150/ijbs.101548 
19. Gu YY, Liu XS, Huang XR et al. Diverse Role of TGF-β in Kidney Disease. Front Cell Dev Biol 2020;8:123w. DOI: 10.3389/fcell.2020.00123
20. Polonikov AV, Ivanov VP, Belugin DA et al. Analysis of common transforming growth factor beta-1 gene polymorphisms in gastric and duodenal ulcer disease: pilot study. J Gastroenterol Hepatol 2007;22(4):555-64. DOI: 10.1111/j.1440-1746.2006.04542.x

For citation:Gaffarova A.S., Beloglazov V.A., Yatskov I.A., Ageyeva E.S., Petrov A.V. The effect of the single nucleotide polymorphism Arg25Pro of TGFB1 gene on clinical and laboratory features and the formation of comorbid pathology associated with cardiovascular risk. Clinical review for general practice. 2026; 7 (6): 60–66 (In Russ.). DOI: 10.47407/kr2026.7.6.00864


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

Scopus
doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru